1 active not recruiting, 1 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow David Ho: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults ART, 10E8.4/iMab, VRC07-523LS - HIV-1-infection | Phase 1 | Active not recruiting | David Ho | 20 | 2023-11-28 | 2026-06-02 |
| 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults 10E8.4/iMab - HIV-1-infection | Phase 1 | Completed | David Ho | 54 | 2019-04-08 | 2023-03-07 |
Antiretroviral Therapy, Highly Active (1) · ibalizumab (1)
Tanzania (1) · United States (1)
David D. Ho, MD (2) · Marco Missanga, MD (1) · Trevor A. Crowell, MD, PhD (1)